Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer Therapies in Subjects With Advanced Solid Tumors

NCT03829436 is registered in ClinicalTrials.gov with Tempest Therapeutics as lead sponsor.

NCT NCT03829436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03829436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer Therapies in Subjects With Advanced Solid Tumors
Lead sponsor
Tempest Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
March 20, 2019
Completion date
September 7, 2022
Enrollment
38 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, colorectal cancer, gastroesophageal cancer, hepatocellular carcinoma, metastatic castration resistant prostate cancer, non-small cell lung cancer, pancreatic cancer, renal cell carcinoma, sarcoma, squamous cell carcinoma of head and neck, triple-negative breast cancer, urothelial carcinoma